Items where Author or Editor is "Hallek, M." - Kölner UniversitätsPublikationsServer

Group by: Item Type | Date | No Grouping

Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Number of items: 214.

2023

Tometten, L., Malin, J. J., Pracht, E., Broeckelmann, P. J., Horn, C., Sprute, R., Langhorst, C. A., Hallek, M., Faetkenheuer, G. and Rybniker, J. (2023). Recurrent SARS-CoV-2 infections in immunodeficiency. Innere Med., 64 (1). S. 84 - 88. Berlin: SPRINGER MEDIZIN. ISSN 2731-7099

2022

Augustin, M., Hallek, M. and Nitschmann, S. (2022). Antibody Therapy in Patients with COVID-19. Internist, 63 (5). S. 573 - 577. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2022). Risk of myocarditis associated with mRNA vaccines for prevention of COVID-19. Internist, 63 (4). S. 461 - 465. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, Max, Hallek, M. and Nitschmann, S. (2022). Myocarditis and pericarditis after COVID-19 mRNA vaccination. Innere Med., 63 (12). S. 1323 - 1327. Berlin: SPRINGER MEDIZIN. ISSN 2731-7099

Thomalla, D., Beckmann, L., Grimm, C., Oliverio, M., Meder, L., Herling, C. D., Nieper, P., Feldmann, T., Merkel, O., Lorsy, E., Guerreiro, A. da Palma, von Jan, J., Kisis, I., Wasserburger, E., Claasen, J., Faitschuk-Meyer, E., Altmueller, J., Nuernberg, P., Yang, T. -P., Lienhard, M., Herwig, R., Kreuzer, K. -A., Pallasch, C. P., Buettner, R., Schaefer, S. C., Hartley, J., Abken, H., Peifer, M., Kashkar, H., Knittel, G., Eichhorst, B., Ullrich, R. T., Herling, M., Reinhardt, H. C., Hallek, M., Schweiger, M. R. and Frenzel, L. P. (2022). Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies. Blood, 140 (20). S. 2113 - 2127. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2021

Augustin, M., Hallek, M. and Nitschmann, S. (2021). Antibody therapy in patients with COVID-19. Internist, 62 (5). S. 572 - 577. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2021). Development of Vaccines for the Prevention of COVID-19-Part 2. Internist, 62 (3). S. 337 - 341. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2021). Development of vaccines for prevention of COVID-19: part 3. Internist, 62 (6). S. 690 - 694. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2021). Vaccine Development for Prevention of COVID-19 in Adolescents. Internist, 62 (12). S. 1360 - 1364. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Niemann, C. U., Kater, A. P., Gregor, M., Cymbalista, F., Buske, C., Hillmen, P., Hallek, M. and Mey, U. (2021). Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 32 (1). S. 23 - 34. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Kron, F., Franz, J., Kron, A. and Hallek, M. (2021). Economics and management of CAR T- cell therapy Status quo and future perspectives. Internist, 62 (6). S. 620 - 627. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

2020

Al-Sawaf, O., Robrecht, S., Fink, A., Ritgen, M., Johansson, P., Staber, P., Jaeger, U., Niemann, C., Pallasch, C., Kreuzer, K., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M. and Eichhorst, B. (2020). The CLL-RT1 trial: A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation. Oncol. Res. Treat., 43 (SUPPL 4). S. 73 - 74. BASEL: KARGER. ISSN 2296-5262

Augustin, M. and Hallek, M. (2020). Current study results underline cautious commenting. Internist, 61 (6). S. 646 - 647. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2020). Morphological and molecular Changes in the Lungs of COVID-19 Patients. Internist, 61 (12). S. 1304 - 1308. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2020). Remdesivir for Patients with COVID-19. Internist, 61 (8). S. 869 - 873. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Augustin, M., Hallek, M. and Nitschmann, S. (2020). Remdesivir for patients with severe COVID-19. Internist, 61 (6). S. 644 - 646. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Borchmann, P., Juehling, A., Goedel, P., Balke-Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Preussner, L., Zadoyan, G., Hanssens, L., Kaiser, A., Jurk, M., Buerger, I, Schneider, D., Dropulic, B., Overstijns, T., Holtick, U., Scheid, C., Miltenyi, S. and Hallek, M. (2020). Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 56 - 57. BASEL: KARGER. ISSN 2296-5262

Borchmann, P., Kobe, C., Pluetschow, A., Greil, R., Meissner, J., Topp, M. S., Ostermann, H., Dierlamm, J., Mohm, J., Thiemer, J., Soekler, M., Kerkhoff, A., Ahlborn, M., Halbsguth, T., Martin, S., Keller, U., Balabanov, S., Pabst, T., Vogelhuber, M., Huettmann, A., Wilhem, M., Zijlstra, J. M., Moccia, A., Broeckelmann, P. J., von Tresckow, B., Fuchs, M., Eich, H., Baues, C., Hallek, M., Diehl, V, Dietlein, M. and Engert, A. (2020). Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group. Oncol. Res. Treat., 43 (SUPPL 4). S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Fuerstenau, M., Bahlo, J., Fink, A. M., Lange, E., Dreger, P., Dreyling, M., Hess, G., Ritgen, M., Kneba, M., Doehner, H., Stilgenbauer, S., Wendtner, C. M., Goede, V., Fischer, K., Boettcher, S., Hallek, M. and Eichhorst, B. (2020). Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia, 34 (3). S. 924 - 929. LONDON: SPRINGERNATURE. ISSN 1476-5551

Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H. H., Mayer, P., Ados, A. Kondo, Wahnschaffe, L., Braun, T., Mueller, T. A., Wagle, P., Bouska, A., Neumann, T., Puetzer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Goex, H. J. M., Rappl, G., Altmueller, J., Kotrova, M., Persigehl, T., Hopfinger, G., Hansmann, M. L., Schloesser, H., Stilgenbauer, S., Duerig, J., Mougiakakos, D., Von Bergwelt-Baildon, M., Roeder, I, Hartmann, S., Hallek, M., Moriggl, R., Brueggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H. and Herling, M. (2020). Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood, 136 (24). S. 2786 - 2803. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Richardson, T., Herling, M., Cruz-Aguilar, M. R., Frenzel, L. P., Hallek, M., Scheid, C. and Holtick, U. (2020). High-dose melphalan and autologous stem cell transplantation in elderly patients >= 70 years is safe and effective - A retrospective analysis. Oncol. Res. Treat., 43 (SUPPL 4). S. 107 - 108. BASEL: KARGER. ISSN 2296-5262

2019

Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Fraser, G., Cramer, P., Demirkan, F., Silva, R. Santucci, Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M-S, Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., Karlsson, C., Hallek, M., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. and Chanan-Khan, A. (2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia, 33 (4). S. 969 - 981. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

2018

Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Langerbeins, P., von Tresckow, J., Maurer, C., Kutsch, N., Lange, E., Kiehl, M., Fischer, K., Stilgenbauer, S., Wendtner, C-M, Goede, V, Hallek, M. and Eichhorst, B. (2018). Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials. Oncol. Res. Treat., 41. S. 166 - 167. BASEL: KARGER. ISSN 2296-5262

Baltin, C. T., Bludau, M., Kron, F., Zander, T., Hallek, M., Hoelscher, A. H. and Schroeder, W. (2018). Profit center analysis of esophagectomy. Economical analysis of transthoracic esophagectomy depending on postoperative complications. Chirurg, 89 (3). S. 229 - 237. NEW YORK: SPRINGER. ISSN 1433-0385

Baumann, F. T., Reike, A., Reimer, V., Schumann, M., Hallek, M., Taaffe, D. R., Newton, R. U. and Galvao, D. A. (2018). Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res. Treat., 170 (1). S. 1 - 14. NEW YORK: SPRINGER. ISSN 1573-7217

Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Fuerstenau, M., Engelke, A., Fink, A. -M, Fischer, K., Kreuzer, K. -A, Ritgen, M., Boettcher, S., Wendtner, C. -M, Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2018). Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia. Oncol. Res. Treat., 41. S. 29 - 31. BASEL: KARGER. ISSN 2296-5262

Frangenberg, A., Glossmann, J-P., Kron, F., Werthebach, M., Froitzheim, A., Wolf, J. and Hallek, M. (2018). Challenges in financing an Oncology Center of Excellence a CCC Business Plan. Oncol. Res. Treat., 41. S. 101 - 102. BASEL: KARGER. ISSN 2296-5262

Frangenberg, A., Glossmann, J. -P., Wolf, J. and Hallek, M. (2018). Utilizing an institution-related cancer registry for executing the registration part of the new Cancer Prevention and Restration Law at the University Hospital of Cologne. Oncol. Res. Treat., 41. S. 127 - 128. BASEL: KARGER. ISSN 2296-5262

Fuerstenau, M., Fink, A-M, Herling, C., Maurer, C., Kutsch, N., de la Serna, J., Coscia, M., Eckert, R., Crespo, M., Bosch, F., Noesslinger, T., Ghia, P., Kater, A. P., Boettcher, S., Ritgen, M., Schilhabel, A., Stilgenbauer, S., Tausch, E., Fischer, K., Hallek, M. and Eichhorst, B. (2018). B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide. Oncol. Res. Treat., 41. S. 172 - 174. BASEL: KARGER. ISSN 2296-5262

Hahn, M., Buerckert, J-P, Luttenberger, C. A., Klebow, S., Hess, M., Al-Maarri, M., Vogt, M., Reissig, S., Hallek, M., Wienecke-Baldacchino, A., Buch, T., Muller, C. P., Pallasch, C. P., Wunderlich, F. T., Waisman, A. and Hoevelmeyer, N. (2018). Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappa B signaling. Leukemia, 32 (1). S. 72 - 83. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Hillmen, P., Soumerai, J., Zelenetz, A., Darif, M., Londhe, A., Xing, G., Huang, J., Lin, M., Byrd, J., Chanan-Khan, A., Furman, R., Hallek, M., Jones, J., Sharman, J., Ferrante, L., Reddy, V., Dreiling, L., Adewoye, H., Dubowy, R., Howes, A. and James, D. (2018). A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukaemia Applicable to Patients Treated with Novel Therapies and Standard of Care. Br. J. Haematol., 181. S. 75 - 76. HOBOKEN: WILEY. ISSN 1365-2141

Holtick, U., Herling, M., Theurich, S., Frenzel, L., Herling, C., Schiller, J., Hallek, M. and Scheid, C. (2018). A phase II study to investigate the efficacy of short-term everolimus in addition to post-transplant cyclophosphamide as graft-versus-host-prophylaxis after allogeneic hematopoietic stem cell transplantation (OCTET-EVER). Oncol. Res. Treat., 41. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262

Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Akylzhanova, G., Cox, K., Estenfelder, S., Wang, J., Edelmann, J., Strefford, J. C., Wojdacz, T. K., Fischer, K., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2018). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia, 32 (2). S. 364 - 376. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Kochanek, M., Boell, B., Shimabukuro-Vornhagen, A., Welte, T., Wieland, U., Pletz, M., Hallek, M., Faetkenheuer, G. and Salzberger, B. (2018). The 2017/2018 Influenza Season - business as usual? A Statement of Medical Societies. Internist, 59 (10). S. 1122 - 1125. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Kochanek, M., Hallek, M., Lehnert, H. and Schellong, S. M. (2018). Internal emergency cases at the interface of outpatient and inpatient - part 2. Internist, 59 (3). S. 217 - 218. NEW YORK: SPRINGER. ISSN 1432-1289

Kochanek, M., Piepereit, A., Boell, B., Shimabukuro-Vornhagen, A. and Hallek, M. (2018). Diagnostic management of fever. Internist, 59 (3). S. 218 - 227. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Kutsch, N., Goede, V, Robrecht, S., Kelma, F., Bahlo, J., Fischer, K., Fink, A. -M, Schlag, R., Lange, E., Weide, R., Dreyling, M., Jaeger, U., Stilgenbauer, S., Doehner, H., Kneba, M., Ritgen, M., Wendtner, C. -M, Hallek, M. and Eichhorst, B. (2018). Treatment response and health-related quality of life during management of chronic lymphocytic leukemia (CLL) - a metaanalysis of 3 phase III studies of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 41. S. 30 - 31. BASEL: KARGER. ISSN 2296-5262

Maurer, C., Fink, A. M., Robrecht, S., Bahlo, J., Fischer, K., Eichhorst, B. and Hallek, M. (2018). First-line treatment and outcome in patients with chronic lymphocytic leukemia (CLL) according to age: a report of the German CLL Study Group (GCLLSG) registry. Oncol. Res. Treat., 41. S. 170 - 172. BASEL: KARGER. ISSN 2296-5262

Pfister, R., Achenbach, S., Boenner, F., Mueller, O. J., Hallek, M., Kochanek, M., Bokemeyer, C., Weissinger, F., Lueftner, D., Baldus, S. and Kelm, M. (2018). Comments on the 2016 position paper of the European Society of Cardiology (ESC) on cardiovascular complications of oncological treatment. Kardiologe, 12 (1). S. 19 - 26. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1864-9726

Pflug, N., Chakupurakal, G., Theurich, S., Holtick, U., Leitzke, S., Chemnitz, J., Scheid, C., Hallek, M. and von Bergwelt-Baildon, M. (2018). Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience. Oncol. Res. Treat., 41. S. 102 - 103. BASEL: KARGER. ISSN 2296-5262

Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Putzer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ferreira, M. S. Ventura, Beier, F., Altmueller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Bruemmendorf, T. H., Nuernberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M. -H., Mustjoki, S., Newrzela, S., Frommolt, P. and Herling, M. (2018). Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat. Commun., 9. LONDON: NATURE PUBLISHING GROUP. ISSN 2041-1723

Vella, G., Krebs, S., Funke, B., Glossmann, J. -P., Zander, T., Schmidt-Wolf, I., Hallek, M. and Wolf, J. (2018). Managing Common Organizational Data across Sites in Comprehensive Cancer Centers - Harmonizing Approaches at the University Hospitals of Cologne and Bonn. Oncol. Res. Treat., 41. S. 127 - 129. BASEL: KARGER. ISSN 2296-5262

2017

Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., Hoechstetter, M., Fink, A., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C., Eichhorst, B., Hallek, M. and Goede, V. (2017). CHARACTERISTICS, TREATMENT, AND OUTCOMES OF >= 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Haematologica, 102. S. 421 - 422. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., M., Hochstaetter, Fink, A. M., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C. M., Eichhorst, B., Hallek, M. and Goede, V. (2017). Characteristics, treatment, and outcomes of >= 80 year old patients with chronic lymphocytic leukemia (CLL) enrolled to prospective trials of the German CLL study group. Oncol. Res. Treat., 40. S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., von Tresckow, J., Cramer, P., Langerbeins, P., Kutsch, N., Wendtner, C. M., Fischer, K., Eichhorst, B., Goede, V. and Hallek, M. (2017). Mode of progression correlates with further clinical outcome of chronic lymphocytic leukemia (CLL). A meta-analysis by the German CLL study group. Oncol. Res. Treat., 40. S. 138 - 139. BASEL: KARGER. ISSN 2296-5262

Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Seiler, T., von Weikersthal, L. Fischer, Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Haematologica, 102. S. 171 - 173. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Tausch, E., Seiler, T., von Weikersthal, Fischer L., Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 40. S. 24 - 25. BASEL: KARGER. ISSN 2296-5262

Edelmann, J., Tausch, E., Landau, D. A., Robrecht, S., Bahlo, J., Fischer, K., Fink, A. M., Bloehdorn, J., Holzmann, K., Boettcher, S., Werner, L., Kneba, M., Gribben, J. G., Neuberg, D. S., Wu, C. J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2017). Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia, 31 (3). S. 734 - 740. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Eichhorst, B. and Hallek, M. (2017). Chronic lymphocytic Leukemia. Treatment Concepts in Transition (2015). Internist, 58 (10). S. 1124 - 1125. NEW YORK: SPRINGER. ISSN 1432-1289

Foelsch, U. R., Hallek, M., Raupach, T. and Hasenfuss, G. (2017). Response to and further development of the Choosing wisely initiative. Internist, 58 (6). S. 527 - 532. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Giannotti, F., Labopin, M., Ruggeri, A., Ehninger, G., Niederwieser, D., Stelljes, M., Stuhler, G., Kroeger, N., Einsele, H., Eder, M., Hallek, M., Glass, B., Finke, J., Ciceri, F., Mohty, M. and Nagler, A. (2017). Outcomes after matched unrelated donor and non-T-cell depleted haploidentical stem cell transplantation in patients >= 60 years with acute myeloid leukemia: A comparative study on behalf of the ALWP of the EBMT. Bone Marrow Transplant., 52. S. S36 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Goede, V., Bahlo, J., Robrecht, S., Al-Sawaf, O., Fink, A. -M., Wendtner, C. -M., Stilgenbauer, S., Fischer, K., Eichhorst, B. and Hallek, M. (2017). CUMULATIVE ILLNESS RATING SCALE PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG. Haematologica, 102. S. 72 - 73. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Greinix, H., Beohou, E., van der Werf, S., Niederwieser, D., Blaise, D., Dreger, P., Arnold, R., Meijer, E., Sengeloev, H., Cornelissen, J., Hallek, M., Socie, G., Chevallier, P., Ganser, A., Milpied, N., Maertens, J., Petersen, E., Afanasyev, B., Ehninger, G., Fegueux, N., Jindra, P., Kroeger, N., Montoto, S., Nagler, A. and Duarte, R. (2017). Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant., 52. S. S61 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Hasenfuss, G., Maerker-Hermann, E., Hallek, M., Sieber, C. C. and Foelsch, U. R. (2017). Choosing Wisely - evidence-based. Internist, 58 (6). S. 525 - 527. NEW YORK: SPRINGER. ISSN 1432-1289

Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Bahlo, J., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). A new prognostic model based on clinical, biological and genetic parameters improves prognostication in early stage CLL patients: results of the prospective CLL1 trial of the German CLL study group. Oncol. Res. Treat., 40. S. 25 - 27. BASEL: KARGER. ISSN 2296-5262

Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Bahlo, J., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31 (12). S. 2833 - 2838. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Jagasia, M., Beohou, E., van der Werf, S., Niederwieser, D., Dreger, P., Meijer, E., Chevallier, P., Sengeloev, H., Blaise, D., Petersen, E., Cornelissen, J. J., Ehninger, G., Gribben, J., Caballero, D., Beguin, Y., Hallek, M., Jindra, P., Fanin, R., Delage, J., Maertens, J., Gedde-Dahl, T., Montoto, S., Kroger, N., Greinix, H. and Duarte, R. (2017). Addition of rituximab in reduced intensity conditioning regimens for B-cell malignancies does not influence transplant outcomes: an EBMT registry analyses. Bone Marrow Transplant., 52. S. S83 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Jawhar, M., Naumann, N., Knut, M., Schneider, B., Ghazzawi, M., Kreuzer, K-A., Hallek, M., Fabarius, A., Score, J., Chase, A., Tapper, W., Reiter, A. and Cross, N. (2017). ZMYM2-FLT3 IS A RARE, RECURRENT, CYTOGENTICALLY CRYPTIC FUSION IN MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA THAT IS RESPONSIVE TO FLT3 INHIBITION. Haematologica, 102. S. 553 - 554. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Jawhar, M., Naumann, N., Knut, M., Score, J., Ghazzawi, M., Schneider, B., Kreuzer, K-A, Hallek, M., Drexler, H. G., Chacko, J., Wallis, L., Fabarius, A., Metzgeroth, G., Hofmann, W-K, Chase, A., Tapper, W., Reiter, A. and Cross, N. C. P. (2017). Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia, 31 (10). S. 2271 - 2275. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Jawhar, M., Naumann, N., Knut, M., Score, J., Ghazzawi, M., Schneider, B., Kreuzer, K. -A., Hallek, M., Chacko, J., Wallis, L., Schwaab, J., Metzgeroth, G., Hofmann, W. -K., Fabarius, A., Chase, A., Tapper, W., Cross, N. C. P. and Reiter, A. (2017). Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasm with eosinophilia. Oncol. Res. Treat., 40. S. 150 - 151. BASEL: KARGER. ISSN 2296-5262

Jerkeman, M., Hallek, M., Dreyling, M., Thieblemont, C., Kimby, E. and Staudt, L. (2017). Targeting of B-cell receptor signalling in B-cell malignancies. J. Intern. Med., 282 (5). S. 415 - 429. HOBOKEN: WILEY. ISSN 1365-2796

Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Wang, J., Fischer, K., Akylzhanova, G., Edelmann, J., Estenfelder, S., Strefford, J., Wojdacz, T., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2017). NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES. Haematologica, 102. S. 228 - 229. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Knittel, G., Korovkina, D., Liedgens, P., Rehkaemper, T., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P. -H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T. and Reinhardt, H. C. (2017). Novel models of high-risk CLL reveal an actionable PARP1 dependence in ATM-defective CLL in vivo. Oncol. Res. Treat., 40. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262

Kraemer, I., Stilgenbauer, S., Dietrich, S., Boettcher, S., Bunjes, D. W., Zeis, M., Stadler, M., Bittenbring, J. T., Uharek, L., Scheid, C., Hegenbart, U., Ho, A., Anthony, D., Hallek, M., Kneba, M., Schmitz, N., Doehner, H. and Dreger, P. (2017). Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial. Bone Marrow Transplant., 52. S. S424 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Kron, F., Kostenko, A., Scheffler, M., Mueller, D., Glossmann, J. -P., Fischer, R., Michels, S., Nogova, L., Hallek, M., Zander, T. and Wolf, J. (2017). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer, 108. S. 134 - 140. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332

Lohmann, G., Vasyutina, E., Bloehdorn, J., Reinart, N., Schneider, J. I., Babu, V., Knittel, G., Crispatzu, G., Mayer, P., Prinz, C., Muenzner, J. K., Biersack, B., Efremov, D. G., Chessa, L., Herling, C. D., Stilgenbauer, S., Hallek, M., Schobert, R., Reinhardt, H. C., Schumacher, B. and Herling, M. (2017). Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. Leukemia, 31 (5). S. 1177 - 1187. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Murawski, N., Amam, J., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Poeschel, V. and Pfreundschuh, M. (2017). Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy. Oncol. Res. Treat., 40. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262

Pasternack, H., Fassunke, J., Plum, P., Chon, S., Merkelbach-Bruse, S., Bruns, C., Perner, S., Hallek, M., Buttner, R., Zander, T., Quaas, A., Weiss, J. and Alakus, H. (2017). Detection of Somatic Alterations in Circulating Cell-free DNA of Esophageal Carcinoma Patients during Primary Staging is Predictive for Post-surgical Tumor Recurrence. J. Mol. Diagn., 19 (2). S. S37 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Pfreundschuh, M., Christofyllakis, K., Altmann, B., Ziepert, M., Haenel, M., Viardot, A., Neubauer, A., Held, G., Truemper, L., Schmidt, C., Kanz, L., Hallek, M., Schmitz, N., Heintges, T., Koelbel, C., Schneider, G., Ruebe, C., Hellwig, D., Poeschel, V. and Murawski, N. (2017). Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL. Oncol. Res. Treat., 40. S. 11 - 12. BASEL: KARGER. ISSN 2296-5262

Sauer, M., Schuldner, M., Hoffmann, N., Cetintas, A., Reiners, K. S., Shatnyeva, O., Hallek, M., Hansen, H. P., Gasser, S. and von Strandmann, E. P. (2017). CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene, 36 (7). S. 933 - 942. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5594

Schiffmann, L. M., Brunold, M., Liwschitz, M., Goede, V., Loges, S., Wroblewski, M., Quaas, A., Alakus, H., Stippel, D., Bruns, C. J., Hallek, M., Kashkar, H., Hacker, U. T. and Coutelle, O. (2017). A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br. J. Cancer, 116 (5). S. 600 - 609. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Stilgenbauer, S., Chyla, B., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., Seymour, J. F., Roberts, A. W., Coutre, S., Jurczak, W., Mulligan, S. P., Puvvada, S., Wendtner, C-M, Davids, M., Boeettcher, S., Cerri, E., Zhou, L., Popovic, R., Poteracki, M., Arzt, J., Kim, S. Y., Verdugo, M., Bhathena, A., Wierda, W. and Hallek, M. (2017). VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL. Haematologica, 102. S. 311 - 313. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D-A, Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E. S., Stilgenbauer, S., Wu, C. J., Kiezun, A., Getz, G. and Brown, J. R. (2017). Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia, 31 (10). S. 2244 - 2248. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D. -A., Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E., Stilgenbauer, S., Wu, C., Kiezun, A., Getz, G. and Brown, J. (2017). GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica, 102. S. 65 - 66. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Vorholt, D., Erlikh, T., Feldkoetter, H., Nickel, N., Hallek, M. and Pallasch, C. (2017). Functional Implications and Interaction of macrophages in the leukemic microenvironment of CLL upon genotoxic stress. Oncol. Res. Treat., 40. S. 141 - 142. BASEL: KARGER. ISSN 2296-5262

2016

Al-Maarri, M., Nickel, N., Roth, A., Hoevelmeyer, N., Hallek, M., Wunderlich, F. T. and Pallasch, C. (2016). AKT ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS PROMOTES TRANSFORMATION TOWARDS AGGRESSIVE RICHTER'S SYNDROME LYMPHOMA. Haematologica, 101. S. 10 - 11. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262

Bahlo, J., Goede, V, Kutsch, N., Fischer, K., Fink, A. -M, Stilgenbauer, S., Bergmann, M., Eichhorst, B. and Hallek, M. (2016). Evaluation of the international prognostic index for chronic lymphocytic leukemia (CLL-IPI) in elderly patients with comorbidities: Analysis of the CLL11 study population. Oncol. Res. Treat., 39. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262

Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M. and Stilgenbauer, S. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385

Cramer, P., Fraser, G., Chanan-Khan, A., Demirkan, F., Silva, Santucci R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. -S, Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A., Balasubramanian, S. and Hallek, M. (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Oncol. Res. Treat., 39. S. 34 - 36. BASEL: KARGER. ISSN 2296-5262

Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Fink, A. M., Maurer, C., Bahlo, J., Kluth, S., Linde, H., Aldaoud, A., Illmer, T., Dengler, J., Klausmann, M., Lathan, B., Al-Sawaf, O., Fischer, K., Wendtner, C. -M, Eichhorst, B. and Hallek, M. (2016). Three years after the start of enrolment: Current data from the prospective CLL-registry of the German CLL Study Group. Oncol. Res. Treat., 39. S. 256 - 257. BASEL: KARGER. ISSN 2296-5262

Fischer, Julia, Hamacher, L., Fries, J., Hallek, M., Cornely, O. A., Kochanek, M. and Boell, B. (2016). Rhodotorula mucilaginosa as a cause of recurrent pulmonary infection and liver infiltration in a patient with CLL. Ann. Hematol., 95 (9). S. 1569 - 1571. NEW YORK: SPRINGER. ISSN 1432-0584

Follows, G., Fischer, K., Bosch, F., Frederiksen, H., Cuneo, A., Ludwig, H., Crompton, N., Maurer, J., Uguen, M., Fingerle-Rowson, G., Hallek, M. and Goede, V. (2016). An updated survival analysis from the CLL11 study in patients with chronic lymphocytic leukaemia treated with obinutuzumab or rituximab in combination with chlorambucil versus chlorambucil alone. Br. J. Haematol., 173. S. 95 - 96. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Fraser, G., Cramer, P., Demirkan, F., Santucci Silva, R., Grosicki, S., Janssens, A., Mayer, J., Dilhuydy, M. S., Pylypenko, H., Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A. and Hallek, M. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica, 101. S. 150 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Freeman, C. L., Dixon, M., Houghton, R., Kreuzer, K-A, Fingerle-Rowson, G., Herling, M., Humphrey, K., Boettcher, S., de Costa, C. S., Iglesias, V., Stilgenbauer, S., Gribben, J., Hallek, M. and Goede, V. (2016). Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia, 30 (8). S. 1763 - 1768. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Ghia, P., Cheson, B. D., Furman, R. R., Hallek, M., Hillmen, P., O'Brien, S. M., Sharman, J. P., Dubowy, R. L., Velasco, B., Waldapfel, C. C., Zelenetz, A. D. and Brown, J. R. (2016). PATTERNS OF IDELALISIB TREATMENT-EMERGENT LYMPHOCYTOSIS IN PATIENTS WITH CLL OR SLL. Haematologica, 101. S. 439 - 440. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Hallek, M. (2016). Treatment of Leukamia Progress through good practical and systematic clinical Research made in Germany. Drug Res., 66. S. S28 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 2194-9387

Hasenfuss, G., Maerker-Hermann, E., Hallek, M. and Foelsch, U. R. (2016). Choosing wisely in internal medicine. Internist, 57 (6). S. 521 - 526. NEW YORK: SPRINGER. ISSN 1432-1289

Hasenfuss, G., Maerker-Hermann, E., Hallek, M. and Sieber, C. (2016). Choosing wisely Primarily the Quality of Indications. Internist, 57 (6). S. 519 - 521. NEW YORK: SPRINGER. ISSN 1432-1289

Holtick, U., Herling, M., Pflug, N., Chakupurakal, G., Leitzke, S., Wolf, D., Hallek, M., Scheid, C. and Chemnitz, J. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol containing treosulfan in an elderly population with AML. Bone Marrow Transplant., 51. S. S442 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Hoster, E., Geisler, C. H., Doorduijn, J., van der Holt, B., Walewski, J., Bloehdorn, J., Ribrag, V., Salles, G., Hallek, M., Pott, C., Szymczyk, M., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., van't Veer, M., Kluin-Nelemans, J. C., Klapper, W., Unterhalt, M., Dreyling, M. and Hermine, O. (2016). Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia, 30 (6). S. 1428 - 1431. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Knittel, G., Korovkina, D., Liedgens, P., Fritz, C., Al-Baldawi, Y., Bahlo, J., Herling, C., Eichhorst, B., Hallek, M., Persigehl, T., Buettner, R. and Reinhardt, H. C. (2016). ESTABLISHMENT OF A PRE-CLINICAL IN VIVO PLATFORM SPANNING LOW-RISK TO HIGH-RISK CLL. Haematologica, 101. S. 9 - 11. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Kron, F., Kostenko, A., Glossmann, J., Hallek, M., Scheffler, M., Zander, T. and Wolf, J. (2016). Economic burden in lung cancer trials: Experience in a Comprehensive Cancer Center in Germany. Oncol. Res. Treat., 39. S. 112 - 113. BASEL: KARGER. ISSN 2296-5262

Kron, F., Kostenko, A., Scheffler, M., Glossmann, J., Fischer, R., Michels, S., Nagoya, L., Hallek, M., Zander, T. and Wolf, J. (2016). Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262

Kron, F., Nadine, K., Kostenko, A., Dohle, I, Mueller, D., Bahlo, J., Bergwelt, M., Eichhorst, B., Hallek, M. and Zander, T. (2016). Profit center analysis of chronic lymphatic leukemia cases: a hospital management perspective. Oncol. Res. Treat., 39. S. 258 - 259. BASEL: KARGER. ISSN 2296-5262

Kusch, M., Labouvie, H., Gerlach, Alexander L. ORCID: 0000-0001-6794-5349, Hellmich, M. and Hallek, M. (2016). Übersicht – Kommt die personalisierte Psychoonkologie? TumorDiagnostik & Therapie, 37 (10). pp. 560-564. Thieme. ISSN 0722-219X

Lehnert, H., Sieber, C. and Hallek, M. (2016). Palliative Medicine. Internist, 57 (10). S. 943 - 946. NEW YORK: SPRINGER. ISSN 1432-1289

Malard, F., Labopin, M., Stuhler, G., Bittenbring, J., Ganser, A., Tischer, J., Michallet, M., Kroeger, N., Schmid, C., Huynh, A., Hallek, M., Savani, B., Mohty, M. and Nagler, A. (2016). Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with high-risk AML in complete remission: a survey from the ALWP of the EBMT. Bone Marrow Transplant., 51. S. S11 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A. M., Pflug, N., Engelke, A., von Tresckow, J., Kovacs, G., Stilgenbauer, S., Wendtner, C-M, Mueller, L., Ritgen, M., Seiler, T., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. Leukemia, 30 (10). S. 2019 - 2026. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Neumann, L., Goeckeritz, E., Hallek, M. and Krause, G. (2016). FUNCTIONAL ROLE OF PI3K-DELTA IN MALIGNANT B CELLS. Haematologica, 101. S. 429 - 430. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Nguyen, P. H., Reinart, N., Krause, G. and Hallek, M. (2016). IN VIVO CHARACTERIZATION OF LYN KINASE IN THE PATHOGENESIS OF CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica, 101. S. 46 - 47. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Nickel, N., Al-Maarri, M., Pal, M., Roth, A., Schaefer, S., Buettner, R., Hallek, M., Wunderlich, T. and Pallasch, C. P. (2016). AKT activation in Chronic Lymphocytic Leukemia cells promotes transformation towards aggressive Richter's syndrome lymphoma. Oncol. Res. Treat., 39. S. 13 - 14. BASEL: KARGER. ISSN 2296-5262

Pohlen, M., Braess, J., Thudium, J., Schmid, C., Kochanek, M., Kreuzer, K. -A, Goerlich, D., Gerth, U., Rhode, C., Mueller-Tidow, C., Stelljes, M., Buechner, T., Schlimok, G., Hallek, M., Waltenberger, J., Hiddemann, W., Berdel, W. E., Heilmeier, B. and Krug, U. (2016). Patients with acute myeloid leukemia admitted to intensive care units: Scores predicting outcome and post-ICU survival. Oncol. Res. Treat., 39. S. 51 - 52. BASEL: KARGER. ISSN 2296-5262

Rawstron, A. C., Fazi, C., Agathangelidis, A., Villamor, N., Letestu, R., Nomdedeu, J., Palacio, C., Stehlikova, O., Kreuzer, K-A, Liptrot, S., O'Brien, D., de Tute, R. M., Marinov, I., Hauwel, M., Spacek, M., Dobber, J., Kater, A. P., Gambell, P., Soosapilla, A., Lozanski, G., Brachtl, G., Lin, K., Boysen, J., Hanson, C., Jorgensen, J. L., Stetler-Stevenson, M., Yuan, C., Broome, H. E., Rassenti, L., Craig, F., Delgado, J., Moreno, C., Bosch, F., Egle, A., Doubek, M., Pospisilova, S., Mulligan, S., Westerman, D., Sanders, C. M., Emerson, R., Robins, H. S., Kirsch, I., Shanafelt, T., Pettitt, A., Kipps, T. J., Wierda, W. G., Cymbalista, F., Hallek, M., Hillmen, P., Montserrat, E. and Ghia, P. (2016). A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia, 30 (4). S. 929 - 937. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Scheid, C., Chemnitz, J., Herling, M., Pflug, N., Theurich, S., Burst, A., Leitzke, S., von Bergwelt-Baildon, M., Hallek, M. and Holtick, U. (2016). A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS FOR HODGKIN'S LYMPHOMA? Haematologica, 101. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Soumerai, J. D., Barrientos, J. C., Hallek, M., Kipps, T. J., Jones, J. A., Xing, G., Yao, N. S., Ysebaert, L., Stilgenbauer, S. and Zelenetz, A. D. (2016). AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3 RANDOMIZED STUDIES. Haematologica, 101. S. 53 - 55. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Vollbrecht, C., Mairinger, F. D., Koitzsch, U., Peifer, M., Koenig, K., Heukamp, L., Crispatzu, G., Wilden, L., Kreuzer, K-A, Hallek, M., Odenthal, M., Herling, C. D. and Buettner, R. (2016). Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing. Oncol. Res. Treat., 39. S. 159 - 160. BASEL: KARGER. ISSN 2296-5262

Volz, C., Zaplatina, A., Siobal, M., Chatterjee, S., Schoettle, J., Meder, L., Florin, A., Koker, M., Buettner, R., Miao, H., Wang, B., Hallek, M., Acker-Palmer, A. S., Heukamp, L. C., Thomas, R. K. and Ullrich, R. (2016). Anti angiogenic treatment induces tumor cell invasion and metastasis via EphA2 signaling in NSCLC. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262

Vorholt, D., Erlikh, T., Nickel, N., Hallek, M. and Pallasch, C. (2016). DIRECT AND INDIRECT MODULATION OF MACROPHAGES IN THE TUMOR MICROENVIRONMENT UPON GENOTOXIC STRESS ALTERS PHAGOCYTIC FUNCTION. Haematologica, 101. S. 421 - 423. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Weiss, J., Knuver, J., Schlaak, M., Kreuzer, K., Hallek, M. and Mauch, C. (2016). Minimal-invasive tumor monitoring of BRAF V600E positive tumors in cell-free plasma DNA. J. Dtsch. Dermatol. Ges., 14. S. 11 - 13. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387

Zimmer, P., Oberste, M., Bloch, W., Schenk, A., Joisten, N., Hartig, P., Wolf, F., Baumann, F. T., Garthe, A., Hallek, M. and Elter, T. (2016). Impact of aerobic exercise training during chemotherapy on cancer related cognitive impairments in patients suffering from acute myeloid leukemia or myelodysplastic syndrome - Study protocol of a randomized placebo-controlled trial. Contemp. Clin. Trials, 49. S. 1 - 6. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1559-2030

van Gorkom, G., van Gelder, M., Ziagkos, D., Koster, L., Koc, Y., van Lint, M., Ciceri, F., Selleslag, D., Blaise, D., Foa, R., Beelen, D., Corradini, P., Moreno, C., Carlson, K., Solano, C., Mueller, L. P., Castagna, L., Tischer, J., Hilgendorf, I., Hallek, M., Bittenbring, J., Theobald, M., Schetelig, J. and Kroeger, N. (2016). Outcomes of mismatched related allogeneic stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant., 51. S. S293 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M, Klaproth, H., Tausch, E., Fischer, K., Wendtner, C-M, Kreuzer, K. -A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262

von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Klaproth, H., Tausch, E., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Oncol. Res. Treat., 39. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262

2015

Bahlo, J., Kutsch, N., Bergmann, M., Byrd, J., Doehner, H., Eichhorst, B., Else, M., Geisler, C., Grever, M., Lepretre, S., Neuberg, D., Oscier, D., Robak, T., Rosenquist, R., Shanafelt, T., Stilgenbauer, S. and Hallek, M. (2015). THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS. Haematologica, 100. S. 313 - 315. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Chakupurakal, G., Garcia-Marquez, M., Shimabukuro-Vorn-hagen, A., Theurichi, S., Scheid, C., Hallek, M., Holtick, U. and von Bergwelt-Baildon, M. (2015). IL-10 producing B-10 cells can be identified as early as 30 days post an allogeneic stem cell transplant and are enriched in the transitional B-cell compartment. Bone Marrow Transplant., 50. S. S176 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584

Coutelle, O., Schiffmann, L. M., Liwschitz, M., Brunold, M., Goede, V., Hallek, M., Kashkar, H. and Hacker, U. T. (2015). Dual targeting of Angiopoetin-2 and VEGF potentiates effective vascular normalisation without inducing empty basement membrane sleeves in xenograft tumours. Br. J. Cancer, 112 (3). S. 495 - 504. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Cramer, P., Chanan-Khan, A., Demirkan, F., Fraser, G., Santucci Silva, R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. S., Loscertales, J., Bartlett, N. L., Avigdor, A., Rule, S., Sun, S., Mahler, M., Salman, M., Howes, A. and Hallek, M. (2015). IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY. Haematologica, 100. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cramer, P., von Tresckow, J., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Wesselmann, J. S., Annolleck, T., Pflug, N., Kovacs, G., Fischer, K., Wendtner, C-M, Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2015). CLL2-BIG, -BAG, -BCG and -BIO: A series of four phase-II trials evaluating a sequential regimen of combined targeted therapy aiming for a total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262

Dietrich, S., Pircher, A., Andrulis, M. A., Peyrade, F., Wendtner, C. -M, Gaehler, A., Follows, G., Dyer, M., Elter, T., Zeiser, R., Herrmann, M., Herold, M., Dearden, C., Haferlach, T., Hallek, M., Huellein, J., Matutes, E., Duerig, J., von Kalle, C., Glimm, H., Froehling, S., Abdel-Wahab, O., Hutter, B., Steurer, M., Ho, A. and Zenz, T. (2015). Treatment of refractory hairy cell leukemia by BRAF-inhibition. Oncol. Res. Treat., 38. S. 119 - 120. BASEL: KARGER. ISSN 2296-5262

Eichhorst, B. and Hallek, M. (2015). Chronic lymphocytic leukemi. Treatment concepts in transition. Internist, 56 (4). S. 374 - 381. NEW YORK: SPRINGER. ISSN 1432-1289

Eichhorst, B., Robak, T., Montserrat, E., Ghia, P., Hillmen, P., Hallek, M. and Buske, C. (2015). Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro). Ann. Oncol., 26. S. V78 - 7. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Engel, L. A., Wittig, S., Bock, F., Sauerbier, L., Scheid, C., Holtick, U., Chemnitz, J-M, Hallek, M., Cursiefen, C. and Steven, P. (2015). Meibography and meibomian gland measurements in ocular graft-versus-host disease. Bone Marrow Transplant., 50 (7). S. 961 - 968. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Fandrey, J. and Hallek, M. (2015). Erythropoiesis. Physiology, pathophysiology, and algorithm for classification of the type of anemia. Internist, 56 (9). S. 970 - 975. NEW YORK: SPRINGER. ISSN 1432-1289

Flamme, H., Krueger, M., Berkessel, A., Hallek, M. and Kreuzer, K. A. (2015). NOVEL NO-ASA DERIVATIVES ARE NEW PROMISING AGENTS IN THE THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SOLID CANCERS. Haematologica, 100. S. 418 - 419. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Flamme, H., Krueger, M., Berkessel, A., Hallek, M. and Kreuzer, K. A. (2015). Novel NO-ASA derivatives are new promising agents in the therapy of chronic lymphocytic leukemia (CLL) and solid cancers. Oncol. Res. Treat., 38. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262

Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Freeman, C., Morschhauser, F., Sehn, L., Dixon, M., Houghton, R., Lamy, T., Fingerle-Rowson, G., Wassner-Fritsch, E., Hallek, M., Salles, G. and Cartron, G. (2015). Pattern of cytokine release in patients with chronic lymphocytic leukaemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR). Br. J. Haematol., 169. S. 64 - 65. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Goeckeritz, E., Kerwien, S., Hallek, M. and Krause, G. (2015). EFFICACY OF PHOSPHATIDYLINOSITOL-3 KINASE INHIBITORS WITH DIVERSE ISOFORM SELECTIVITY PROFILES FOR INHIBITING THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS. Haematologica, 100. S. 227 - 229. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Goede, V., Fischer, K., Engelke, A., Schlag, R., Lepretre, S., Montero, L. F. C., Montillo, M., Fegan, C., Asikanius, E., Humphrey, K., Fingerle-Rowson, G. and Hallek, M. (2015). Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia, 29 (7). S. 1602 - 1606. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Goede, V. and Hallek, M. (2015). Chronic lymphocytic leukemia in elderly patients. Onkologe, 21 (6). S. 486 - 493. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Hallek, M. (2015). Anemias. Internist, 56 (9). S. 969 - 970. NEW YORK: SPRINGER. ISSN 1432-1289

Hallek, M. (2015). Molecular Basis of Leukemia Systematic clinical and preclinical Research. Internist, 56 (4). S. 331 - 333. NEW YORK: SPRINGER. ISSN 1432-1289

Heimann, S. M., Vehreschild, J. J., Cornely, O. A., Wisplinghoff, H., Hallek, M., Goldbrunner, R., Boettiger, B. W., Goeser, T., Hoelscher, A., Baldus, S., Mueller, F., Jazmati, N., Wingen, S., Franke, B. and Vehreschild, M. J. G. T. (2015). Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection, 43 (6). S. 707 - 715. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1439-0973

Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Huelsemann, M. F., Patz, M., Beckmann, L., Brinkmann, K., Otto, T., Fandrey, J., Becker, H. J., Theurich, S., von Bergwelt-Baildon, M., Pallasch, C. P., Zahedi, R. P., Kashkar, H., Reinhardt, H. C., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2015). Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia, 29 (4). S. 981 - 985. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Kochanek, M., Boell, B., Shimabukuro-Vornhagen, A., Michels, G., Barbara, W., Hansen, D., Hallek, M., Faetkenheuer, G. and von Bergwelt-Baildon, M. (2015). Personal Needs of an Intensive Care Unit under Consideration of current Hygiene Guidelines An explorative Analysis. Dtsch. Med. Wochenschr., 140 (14). S. E136 - 6. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Kovacs, G., Bahlo, J., Kluth, S., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Langerbeins, P., Gross-Opphoff-Mueller, C., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Hallek, M., Eichhorst, B. and Goede, V. (2015). Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262

Krause, G., Baki, I., Kerwien, S., Knoedgen, E., Neumann, L., Heider, K. -H. and Hallek, M. (2015). CYTOTOXICITY FOR CHRONIC LYMPHOCYTIC LEUKEMIA CELLS OF THE CD37 ANTIBODY BI 836826 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS OR PI3K INHIBITORS. Haematologica, 100. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Munir, T., Hillmen, P., Eradat, H., Ghia, P., O'Brien, S., Furman, R., Coutre, S., Sharman, J., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Lamanna, N., Hallek, M., Coiffier, B., Pettitt, A., Kim, Y., Jahn, T. and Wagner, L. (2015). Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results. Br. J. Haematol., 169. S. 53 - 54. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141

Pflug, N., Kluth, S., Vehreschild, J. J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A. -M, von Bergwelt-Baildon, M., Hallek, M., Cornely, O. A. and Vehreschild, M. J. G. T. (2015). Impact of antibiotic treatment modulating the intestinal microbiota on the efficacy of antineoplastic treatment for chronic lymphatic leukaemia or relapsed lymphoma. Oncol. Res. Treat., 38. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262

Pflug, N., Maurer, C., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A. -M., Eichhorst, B., Kreuzer, K. -A., Tausch, E., Stilgenbauer, S., Boettcher, S., Doehner, H., Kneba, M., Hallek, M., Wendtner, C. -M., Bergmann, M. and Fischer, K. (2015). Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Savani, B., Labopin, M., Polge, E., Niederwieser, D., Ganser, A., Ehninger, G., Bornhaeuser, M., Renate, A., Finke, J., Kroeger, N., Craddock, C., Schwerdtfeger, R., Hallek, M., Jindra, P., Mohty, M. and Nagler, A. (2015). Influence of HLA-matching after reduced intensity conditioning regimen and unrelated donor allo-SCT for acute leukemia in patients older than 50 years - a report from the acute leukemia working party of the EBMT. Bone Marrow Transplant., 50. S. S28 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Scheid, C., Blommer, J., Holtick, U., Chemnitz, J., Malchau, G., Streichert, T. and Hallek, M. (2015). Using IgM hevylite to distinguish MGUS from malignant disorders with clonal IgM Paraprotein. Oncol. Res. Treat., 38. S. 239 - 240. BASEL: KARGER. ISSN 2296-5262

Scheid, C., Holtick, U., Bornhaeuser, M., Kroeger, N., Ganser, A., Arnold, R., Dreger, P., Stuhler, G., Theobald, M., Peschel, C., Hallek, M., Niederwieser, D., Finke, J., Hertenstein, B. and Beelen, D. (2015). Effects of Busulfan dose and administration route on transplantation outcome in adult patients with AML or MDS - a retrospective analysis of the German transplant registry DRST. Bone Marrow Transplant., 50. S. S224 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Stilgenbauer, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D. F., Chu, A. D., Hallek, M. and O'Brien, S. (2015). Results from the phase 2 RESONATE (TM)-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p. Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262

Stilgenbauer, S., Schleinitz, T. Aurran, Hallek, M., Lang, F., Offner, F., Rossi, J. -F., Schroyens, W., Van Den Neste, E., Ysebaert, L., Blum, P., Hocke, J., Kress, U. U. and Zenz, T. (2015). PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Haematologica, 100. S. 225 - 227. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Tausch, E., Landau, D., Taylor-Weiner, A., Stewart, C., Reiter, J., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Boettcher, S., Cibulskis, K., Mertens, D., Sougnez, C., Rosenberg, M., Hess, J., Carter, S., Edelmann, J., Kless, S., Fink, A., Fischer, K., Ritgen, M., Kneba, M., Gabriel, S., Lander, E., Nowak, M., Doehner, H., Hallek, M., Neuberg, D., Getz, G., Stilgenbauer, S. and Wu, C. (2015). WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS. Haematologica, 100. S. 335 - 337. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Vasyutina, E., Boucas, J. M., Bloehdorn, J., Aszyk, C., Crispatzu, G., Stiefelhagen, M., Breuer, A., Mayer, P., Lengerke, C., Doehner, H., Beutner, D., Rosenwald, A., Stilgenbauer, S., Hallek, M., Benner, A. and Herling, M. (2015). The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia, 29 (10). S. 2003 - 2015. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Vondey, V., Kuckertz, M., Goeckeritz, E., Hallek, M. and Krause, G. (2015). FUNCTIONAL INVOLVEMENT OF THE SRC KINASE LYN IN THE SURVIVAL OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS VIA MAINTENANCE OF ANTI-APOPTOTIC B CELL RECEPTOR SIGNALING. Haematologica, 100. S. 50 - 52. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

2014

Berg, V, Vartak, N., Claasen, J., Rusch, M., Waldmann, H., Bastiaens, P., Hedberg, C., Pallasch, C., Hallek, M., Wendtner, C. and Frenzel, L. (2014). CD95 sensitivity of CLL cells is dependent on palmitoylation and controlled by a complex molecular network including miRNAs. Oncol. Res. Treat., 37. S. 237 - 238. BASEL: KARGER. ISSN 2296-5262

Bey, I., Bergatt-Kuhl, B., Arndt, S., Treppner, S., Schmidt-Wolf, I., Hallek, M. and Wolf, J. (2014). 8 years patient navigators in the interdisciplinary tumor ambulance of CIO Koln Bonn - a role model for other cancer centers?! Oncol. Res. Treat., 37. S. 94 - 96. BASEL: KARGER. ISSN 2296-5262

Edelmann, J., Haferlach, C., Saub, J., Teleanu, V, Florence, C., Leblonde, V, Delmer, A., Buehler, A., Gribben, J. G., Hallek, M., Doehner, H. and Stilgenbauer, S. (2014). Genomic characterization of primary ultra high-risk and refractory chronic lymphocytic leukemia: Results from the CLL2O trial. Oncol. Res. Treat., 37. S. 220 - 221. BASEL: KARGER. ISSN 2296-5262

Fischer, K., Bahlo, J., Fink, A. -M., Busch, R., Boettcher, S., Kreuzer, K. -A., Maurer, C., Mayer, J., Dreger, P., Kneba, M., Doehner, H., Wendtner, C. -M., Stilgenbauer, S., Hallek, M. and Eichhorst, B. (2014). Long Term Remissions After FCR Chemoimmunotherapy In Patients With CLL. Oncol. Res. Treat., 37. S. 86 - 87. BASEL: KARGER. ISSN 2296-5262

Flamme, H., Krallmann, S., Poll-Wolbeck, S. J., Krueger, M., Berkessel, A., Hallek, M. and Kreuzer, K. -A (2014). Novel NO-ASA derivatives are new promising agents in the therapy of chronic lymphocytic leukemia (CLL), other hematologic neoplasia and solid tumors. Oncol. Res. Treat., 37. S. 221 - 222. BASEL: KARGER. ISSN 2296-5262

Glossmann, J. -P., Kron, M., Bernschein, A., Funke, B., Goergen, P., Schmidt-Wolf, I., Hallek, M. and Wolf, J. (2014). Performance-based cost allocation in a Comprehensive Cancer Center. Oncol. Res. Treat., 37. S. 33 - 34. BASEL: KARGER. ISSN 2296-5262

Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., Dela Serna, J., Dilhuydy, M. S., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Langerak, A. W., Ritgen, M., Stilgenbauer, S., Doehner, H., Asikanius, E., Humphrey, K., Wenger, M. K. and Hallek, M. (2014). Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial. Br. J. Haematol., 165. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141

Hallek, M., Coutre, S. E., Furman, R. R., Sharman, J. P., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Ruppert, S., Schuster, A. and Kroenig, H. (2014). 2nd analysis of a phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Idelalisib and Rituximab for previously treated patients with chronic lymphocytic leukemia. Oncol. Res. Treat., 37. S. 183 - 184. BASEL: KARGER. ISSN 2296-5262

Hallek, M., Hillmen, P., Furman, R. R., Coutre, S. E., Sharman, J. P., Pagel, J. M., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Erwin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., O'Brien, S. M., Cheson, B. D., Ruppert, S., Kroenig, H. and Schuster, A. (2014). Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL. Oncol. Res. Treat., 37. S. 52 - 54. BASEL: KARGER. ISSN 2296-5262

Huelsduenker, T., Mierau, A., Baumann, F., Elter, T., Hallek, M., Bloch, W. and Zimmer, P. (2014). Cortical activity during exercise in B-Non-Hotgkinlymphoma (B-NHL) patients and healthy controls. Oncol. Res. Treat., 37. S. 113 - 115. BASEL: KARGER. ISSN 2296-5262

Huelsemann, M., Baatout, D., Kintzele, L., Becker, H. J., Theurich, S., von Berwelt-Baildon, M., Pallasch, C. P., Hallek, M., Wendtner, C. M. and Frenzel, L. P. (2014). HYPOXIA - A CENTRAL MICROENVIRONMENTAL DETERMINANT OF PROLIFERATION AND DRUG-RESISTANCE OF PRIMARY CLL CELLS. Haematologica, 99. S. 39 - 41. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Huelsemann, M. F., Theurich, S., Becker, H. J., Pallasch, C., von Bergwelt-Baildon, M., Hallek, M., Wendtner, C. -M and Frenzel, L. P. (2014). p38 controls sensitivity to BH3 mimetics in CLL via regulation of Mcl-1. Oncol. Res. Treat., 37. S. 222 - 223. BASEL: KARGER. ISSN 2296-5262

Krallmann, S., Liakos, A., Flamme, H., Poll-Wolbeck, S. J., Krueger, M., Berkessel, A., Hallek, M. and Kreuzer, K-A (2014). Modifications of Nitric Oxide Donating Aspirin (NO-ASA): Enhanced sensitivity and selectivity towards TP53 mutated chronic lymphocytic leukemia (CLL) cells. Oncol. Res. Treat., 37. S. 52 - 53. BASEL: KARGER. ISSN 2296-5262

Kreuzer, K. -A. and Hallek, M. (2014). Incidental finding lymphocytosis. From normal variants up to leukemia. Internist, 55 (10). S. 1131 - 1139. NEW YORK: SPRINGER. ISSN 1432-1289

Kron, F., Glossmann, J. P., Lotze, M., Barsoum, M., Winters, S., Normolle, D., Boyiadzis, M., Socinski, M., Bernschein, A., Schmidt-Wolf, I., Funke, B., Meyer, M., von Levetzow, C., Leitzke, S., Hellmich, M., Scheid, C., Kreuzer, K. -A., Kostenko, A., Waldschmidt, D., Heukamp, L., Zander, T., Scheffler, M., Hallek, M. and Wolf, J. (2014). A benchmark study of cancer patient outcome in two Comprehensive Cancer Centers in the US and Germany. Oncol. Res. Treat., 37. S. 95 - 96. BASEL: KARGER. ISSN 2296-5262

Kusch, M., Labouvie, H., Hein-Nau, B., Schwarzkamp, U., Wolf, J. and Hallek, M. (2014). Integreated Pschyo Oncology. Dtsch. Med. Wochenschr., 139 (46). S. 2357 - 2361. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

Langerbeins, P., Busch, R., Schweighofer, C. D., Mueller, C., Cramer, P., Fink, A. M., Faetkenheuer, G., Hartmann, P., Stilgenbauer, S., Boettcher, S., Wendtner, C. M., Hallek, M. and Eichhorst, B. (2014). SEVERE INFECTIONS ARE MORE COMMON IN PHYSICALLY FIT CLL PATIENTS WITH FCR-THERAPY COMPARED TO BR: RESULTS OF THE INTERMIN-ANALYSIS OF THE CLL10 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Langerbeins, P., Busch, R., Schweighofer, C. D., Mueller, C., Fischer, K., Fink, A. -M., Cramer, P., Faetkenheuer, G., Hartmann, P., Stilgenbauer, S., Boettcher, S., Wendtner, C. -M., Hallek, M. and Eichhorst, B. (2014). More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group. Oncol. Res. Treat., 37. S. 185 - 186. BASEL: KARGER. ISSN 2296-5262

Loeschcke, K., Fink, A., Bahlo, J., Westermann, A., Zey, A., Fischer, K., Wendtner, C. M., Noesslinger, T., Ghia, P., Bosch, F., Kater, A. P., Kreuzer, K. A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 587 - 589. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Maerker-Hermann, E. and Hallek, M. (2014). Random Laboratory Findings in Internal Medicine. Internist, 55 (10). S. 1129 - 1131. NEW YORK: SPRINGER. ISSN 1432-1289

Mueller, C., Cymbalista, F., Schweighofer, C., Busch, R., Porcher, R., Langerbeins, P., Cazin, B., Fink, A. -M., Dreyfus, B., Ibach, S., Lepretre, S., Fischer, K., Vehling-Kaiser, U., Eichhorst, B., Bergmann, M. A., Wendtner, C. -M., Stilgenbauer, S., Doehner, H., Leblond, V., Hallek, M. and Levy, V. (2014). Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262

Murawski, N., Pfreundschuh, M., Zeynalova, S., Poeschel, V., Haenel, M., Held, G., Schmitz, N., Viardot, A., Schmidt, C., Hallek, M., Witzens-Harig, M., Truemper, L., Rixecker, T. and Zwick, C. (2014). Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann. Oncol., 25 (9). S. 1800 - 1807. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Nagler, A., Labopin, M., Shimoni, A., Beelen, D., Kyrcz-Krzemien, S., Schufer-Eckart, K., Volin, L., Hallek, M., Griskevicius, L., Blau, I. Wolfgang, Casper, J., Ciceri, F. and Mohty, M. (2014). TREOSULFAN BASED CONDITIONING PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT) FOR ACUTE MYELOGENOUS LEUKEMIA (AML): A RETROSPECTIVE ANALYSIS FROM THE ALWP OF THE EBMT. Bone Marrow Transplant., 49. S. S7 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365

Rancea, M., Skoetz, N., Trelle, S., da Costa, B. R., Engert, A., Fischer, K., Hallek, M. and Eichhorst, B. (2014). FIRST-LINE TREATMENT STRATEGIES FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY RESULTS OF A NETWORK META-ANALYSIS. Haematologica, 99. S. 58 - 59. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Schwamb, J., Reinart, N., Vorholt, D., Ristovska, V, Ulas, T., Leskov, I, Braun, C., Hemann, M., Schultze, J. L., Hallek, M. and Pallasch, C. P. (2014). Phagocytic function of macrophages is impaired by CLL and high-grade lymphoma progression and can be highly effectively restored by chemo-immunotherapy. Oncol. Res. Treat., 37. S. 236 - 238. BASEL: KARGER. ISSN 2296-5262

Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Hillmen, P., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S. and Stilgenbauer, S. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Leuk. Res., 38. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 0145-2126

Starbatty, B., Glossmann, J-P, Funke, B., Hallek, M. and Wolf, J. (2014). Standard Operating Procedures help to implement national guidelines by incorporating center specific assets. Oncol. Res. Treat., 37. S. 83 - 84. BASEL: KARGER. ISSN 2296-5262

Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Rabenhorst, A., Hartmann, K., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Exp. Dermatol., 23 (3). S. E25 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625

Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262

Westermann, A., Fink, A., Zey, A., Wesselmann, J. S., Busch, R., Fischer, K., Wendtner, C., Kreuzer, K-A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). Screening supported by a central review allows a precise selection of the population for maintenance therapy within the CLLM1 trial of the German CLL Study Group. Oncol. Res. Treat., 37. S. 85 - 86. BASEL: KARGER. ISSN 2296-5262

2013

Hoehler, T., von Wichert, G., Schimanski, C., Kanzler, S., Moehler, M. H., Hinke, A., Seufferlein, T., Siebler, J., Hochhaus, A., Arnold, D., Hallek, M., Hofheinz, R. and Hacker, U. T. (2013). Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. Br. J. Cancer, 109 (6). S. 1408 - 1414. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Maurer, C. and Hallek, M. (2013). Chronic lymphocytic leukemia. Dtsch. Med. Wochenschr., 138 (42). S. 2152 - 2162. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-4413

2012

Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924

Engelke, A., Mueller, C. and Hallek, M. (2012). Chronic lymphocytic leukemia. Onkologe, 18 (12). S. 1115 - 1120. NEW YORK: SPRINGER. ISSN 0947-8965

Hallek, M. and Schroeter, T. (2012). The future of clinical training in internal medicine in Germany. Dtsch. Med. Wochenschr., 137 (49). S. 2591 - 2595. STUTTGART: GEORG THIEME VERLAG KG. ISSN 0012-0472

Liss, B. J., Vehreschild, J. J., Cornely, O. A., Hallek, M., Faetkenheuer, G., Wisplinghoff, H., Seifert, H. and Vehreschild, M. J. G. T. (2012). Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection, 40 (6). S. 613 - 620. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 0300-8126

Ullrich, R. T., Zander, T., Wolf, J. and Hallek, M. (2012). Personalised treatment of lung cancer. Dtsch. Med. Wochenschr., 137 (42). S. 2179 - 2181. STUTTGART: GEORG THIEME VERLAG KG. ISSN 0012-0472

2011

Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Wuerthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., Harnischmacher, U., Wilkens, A., Farowski, F., Karthaus, M., Lehrnbecher, T., Ullmann, A. J., Hallek, M. and Groll, A. H. (2011). Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis. Antimicrob. Agents Chemother., 55 (12). S. 5798 - 5804. WASHINGTON: AMER SOC MICROBIOLOGY. ISSN 0066-4804

Eichhorst, B., Dreyling, M., Robak, T., Montserrat, E. and Hallek, M. (2011). Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 22. S. vi50 - 5. OXFORD: OXFORD UNIV PRESS. ISSN 0923-7534

2010

Goede, V., Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., Augustin, H. G., Schmiegel, W., Hallek, M. and Hacker, U. T. (2010). Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br. J. Cancer, 103 (9). S. 1407 - 1415. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827

Hacker, U., Hallek, M. and Kubicka, S. (2010). Multimodality therapy of colorectal cancer. Internist, 51 (11). S. 1366 - 1372. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736

Shehata, M., Demirtas, D., Schnabl, S., Hilgarth, M., Hubmann, R., Fonatsch, C., Schwarzinger, I., Hopfinger, G., Eigenberger, K., Heintel, D., Porpaczy, E., Vanura, K., Hauswirth, A., Schwarzmeier, J. D., Gaiger, A., Stilgenbauer, S., Hallek, M., Bilban, M. and Jaeger, U. (2010). Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia, 24 (12). S. 2122 - 2128. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924

Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Haebe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2010). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24 (12). S. 2072 - 2080. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924

This list was generated on Fri Apr 19 10:22:58 2024 CEST.

Export as	Atom RSS 1.0 RSS 2.0